1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study

BACKGROUND: In the PROVENT phase 3 pre-exposure prophylaxis study, AZD7442 (tixagevimab/cilgavimab) reduced symptomatic COVID-19 by 76.7% vs placebo at primary analysis (P< 0.001; median follow-up: 83 days) and was well tolerated. Here, we report final safety from PROVENT at ∼15 months of follow-...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Myron J, Ustianowski, Andrew, De Wit, Stéphane, Beavon, Rohini, Thissen, Jesse, Seegobin, Seth, Streicher, Katie, Kiazand, Alexandre, Esser, Mark T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677955/
http://dx.doi.org/10.1093/ofid/ofad500.1191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677955/
http://dx.doi.org/10.1093/ofid/ofad500.1191

Ejemplares similares